GSK plc unveiled encouraging results from its pivotal Eagle-1 phase 3 trial for gepotidacin, a potential breakthrough oral antibiotic for uncomplicated urogenital gonorrhoea (GC) in adolescents and adults.
During DCAT this year, CEO Gaston Salinas from Botanical Solution Inc., (BSI), sat down with Liza Laws, the senior editor of OSP and BPR to discuss his company’s pioneering work in revolutionizing vaccine adjuvant production.
Bormioli Pharma creates pharmaceutical packaging for drug stability, safety, and sustainability, partnering with global health leaders and says it stands at the forefront of sustainability.
Bios Health Group, a leading strategic and investment partner for life science companies and investors, has officially introduced the Bios Innovation Circle.
Qinecsa Solutions (Qinecsa), a lead company in technology-driven end-to-end pharmacovigilance solutions has announced its acquisition of Insife ApS (Insife), a Danish-based firm specializing in innovative pharmacovigilance platforms.
Charles River Laboratories International, Inc. has unveiled its Alternative Methods Advancement Project (AMAP), a strong initiative aimed at changing drug discovery and development by exploring alternatives to animal testing.
In a recent discussion with Jan Vertommen, vice president and head of commercial development for the small molecules division at Lonza, key insights were shared regarding the pharmaceutical industry's current landscape and future trajectory.
Within the rapidly evolving landscape of decentralized clinical trials (DCTs), one critical challenge persists: the accurate monitoring of cough symptoms.
Michael Fronstin, global head of client partnership and commercialization at the company said the combination of Oracle’s life sciences expertise and platform technology help CROs win more business and run trials more efficiently.
AstraZeneca's latest modelling analysis, IMPACT CKD, presented at the 2024 ISN World Congress of Nephrology (WCN'24) in Buenos Aires, paints a concerning picture of the future of chronic kidney disease (CKD) across eight countries.
The European Commission has granted Orphan Medicinal Product designation for zatolmilast an investigational treatment for Fragile X syndrome (FXS), a leading cause of inherited intellectual disability and autism.
Yesterday's migraine treatment breakthrough, though amidst a complex journey to find a cure, still promises a dramatic impact despite the absence of a 'magic bullet.'
In a groundbreaking revelation, a study conducted by RCSI University of Medicine and Health Sciences and Children’s Health Ireland has confirmed the safety and efficacy of a Cystic Fibrosis drug in newborns as young as four weeks old.
Andaman7, a free healthcare app aiming to revolutionize patient engagement and streamline communication between patients and researchers, has unveiled its latest update, Andaman7 version 5, featuring advanced artificial intelligence (AI) capabilities.
In a landmark development poised to reshape the landscape of medical diagnostics, the US Food and Drug Administration (FDA) has officially sanctioned Prenosis' pioneering artificial intelligence (AI) tool designed for the early detection of sepsis.
GSK's Jemperli (dostarlimab) has been approved for use within NHS Scotland, marking a significant step in the treatment of eligible endometrial cancer patients in the region.
Pharming Group N.V. has declared the successful enrollment completion in its phase 3 clinical trial of leniolisib, an investigational drug designed for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS).
In an exclusive interview with Dr Vanessa Zann, (pictured below) executive drug development consultant at Quotient Sciences, OSP delved into the forefront of pharmaceutical research and development.
In February, Trialbee announced its Omnichannel Network partnership with Massive Bio, a global leader in AI-enabled patient journey mapping platform to help better connect cancer patients with their oncologists/hematologists in clinical trials.
In an overwhelming response to the news that SimBioSys and General Inception had joined forces to use advanced AI and biophysical modeling, to gain deeper insights into tumor biology, the industry has spoken.
Molecure S.A., a leading biotechnology company focused on drug discovery and development, has unveiled its annual report for 2023 at the start of the new financial year.
Precision oncology innovator SimBioSys and General Inception have joined forces in a strategic partnership aimed at revolutionizing cancer drug development.
Dr Laura Trotta joined CluePoints in 2015 and moved into her current role as vice president of research in January 2022, where she leads a team of research scientists responsible for developing new statistical and machine learning algorithms to assess...
In an important announcement today (April 2), Hutchmed and Innovent jointly revealed the acceptance of their New Drug Application (NDA) in China for the combination of Fruquintinib with Sintilimab.
OSP was lucky enough to talk to David Menzies (pictured), executive director, technology solutions at ICON to find out how he thinks the pharma industry needs to overcome the real-world data challenges.
Beacon Biosignals made waves in the healthcare tech sector today with the announcement of FDA 510(k) clearance for a progressive machine learning software designed to change the analysis of sleep patterns.
OSP senior editor, Liza Laws, took some time at SCOPE 2024 in Orlando earlier in the year to speak with two female-focused members of the Clinical Trials Media (CTM) team, Katherine Seay and Veronica Berk to find out how.
David Menzies is the executive director of technology solutions at ICON, a company providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device, and government and public health organisations.
In an exciting collaboration, modern mental health company, Clerkenwell Health, and Beckley Psytech, a clinical-stage biotechnology company, have launched a phase 2a study aimed at investigating a potential breakthrough treatment for alcohol use disorder...
Today (March 26) One2Treat, a progressive startup specializing in digital health solutions, has launched a forward-thinking approach aimed at tackling key challenges in the biopharma industry.
Medtech startup Metyos has secured €2.3 million in pre-seed funding to advance its mission of improving the lives of chronic kidney disease (CKD) patients worldwide.
Patrick Hughes, co-founder and chief commercial officer of Cluepoints and OSP caught up for an in-person discussion during SCOPE 2024 to find out what developments the company had been working on and how they are benefiting from using AI.
With the pharma and healthcare landscape increasingly being shaped by artificial intelligence (AI), the US Food and Drug Administration (FDA) has taken proactive steps to outline a comprehensive strategy for regulating AI in medical products.
Yesterday (March 18) PureTech Health plc announced the completion of the acquisition of its founded entity, Karuna Therapeutics, Inc., by Bristol Myers Squibb for a staggering $14 billion.
The curtains have risen on DCAT 2024 in the vibrant heart of New York City, and leading pharmaceutical companies from around the world have converged for a week of innovation, collaboration, and strategic dialogue.
In an encouraging development, neuromodulation, a form of bioelectric medicine, has emerged as a promising avenue for enhancing health by regulating the nervous system.
On Friday (March 15) leading pharma Auxilius Pharma announced promising results from the first-in-human clinical trial of its originative product-in-development, AUX-001.